% | $
Quotes you view appear here for quick access.

Pacific Biosciences of California, Inc. Message Board 8 posts  |  Last Activity: Mar 24, 2015 3:23 PM Member since: Apr 23, 2013
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • by Mar 24, 2015 3:23 PM Flag

    Sentiment: Buy

  • Reply to

    New PR

    by nanoweasel2005 Mar 23, 2015 7:58 AM Mar 23, 2015 11:42 AM Flag


  • Reply to

    Huge Threat to PacBio

    by maitrikaruna Feb 25, 2015 4:29 PM Feb 26, 2015 10:49 AM Flag

    Didn't you post the same gloom and doom about Nanopore? Where are they at with that error prone beta test? LOL. 10x is years from anything, if anything (with big IF). Just raising monies, stealing Pacbio's leftover employees, etc. With every post you reveal how stupid you really are. Keep em coming! We share and enjoy your coments....keep posting friend!

  • Reply to

    With the FDA showing signs of coming to its senses

    by eiretekk Feb 20, 2015 1:51 PM Feb 25, 2015 10:47 AM Flag

    GTFOH....A salesman....BHAAAHHH. Enough said. LOL.

    Sentiment: Hold

  • Reply to

    With the FDA showing signs of coming to its senses

    by eiretekk Feb 20, 2015 1:51 PM Feb 24, 2015 10:54 AM Flag

    Wrong! They need not "convince" anyone of anything. If you actually performed any NGS across these platforms you'd know the caveats/limitations of each system. You don't push sales on scientists...the science does the selling. At this point, all PACB needs is a homolog to MiSeq in terms of instrument and reagent cost. Then the gap will close. This is coming sooner than later.

    Sentiment: Hold

  • Reply to

    The pieces of the puzzle are coming together

    by Feb 9, 2015 3:58 PM Feb 10, 2015 7:31 AM Flag

    LOL! We will see.

  • Roche Buys German Genomics Firm Signature Diagnostics

    Feb 09, 2015 | a GenomeWeb staff reporter
    NEW YORK (GenomeWeb) – Continuing a buying spree, Roche today announced it acquired German translational oncology and genomics firm Signature Diagnostics for an undisclosed amount.

    Based in Potsdam, Signature develops large blood plasma and tissue biobanks in cancers, including lung and colorectal cancer. The biobanks are constructed from multicenter prospective clinical studies, and Signature uses the samples, along with accompanying clinical progression and genetic data, to develop and validate circulating cell-free DNA-based tests. The tests, Roche said, could advance non-invasive treatment response monitoring for cancer patients.

    Noting the importance of biobanks in research into the origins of diseases such as cancer, Roche Diagnostics COO Roland Diggelmann said, "Signature represents a unique bridge between high-value cancer biobanks and [next-generation sequencing] assay development." He added that biobanks can be used for biomarker discovery and hypothesis testing with pharma.

    Roche will leverage Signature's capabilities to accelerate the development of NGS-based diagnostics, he said. In the fall of 2013, Signature told GenomeWeb that it had developed a plasma-based ultradeep sequencing test to monitor colorectal cancer patients and detect metastasis in the early stages.

    Roche will integrate Signature into its sequencing unit and will continue to expand the company's genomic signature portfolio, it said. Signature's tests are for research use only.

    The acquisition is the latest by Roche, which has been on a buying binge in the omics and molecular diagnostics space during the past year. In December, it bought informatics shop Bina Technologies and non-invasive prenatal testing firm Ariosa Diagnostics. Last spring, it acquired NGS firm Genia and point-of-care molecular diagnostics company Iquum.

    Roche also acquired NGS sample preparation tec

  • Feb 4, 2015 12:13 PM Flag

    Yup, 50% reduction in booked instruments coupled with longer than expected 2016 release of new instrument. People moving money in the interim.

6.15-0.28(-4.35%)Apr 17 4:00 PMEDT